Cilta-Talq Fusion Study
Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 31 patients (estimated)
- Sponsors
- Medical College of Wisconsin
- Tags
- Bispecific Antibody, GPRC5D, Pre-CAR T
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 2177
- NCT Identifier
- NCT07093554
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.